These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11073845)

  • 1. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events.
    van Lennep JE; Westerveld HT; van Lennep HW; Zwinderman AH; Erkelens DW; van der Wall EE
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2408-13. PubMed ID: 11073845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography.
    Westerveld HT; van Lennep JE; van Lennep HW; Liem AH; de Boo JA; van der Schouw YT; Erkelens DW
    Arterioscler Thromb Vasc Biol; 1998 Jul; 18(7):1101-7. PubMed ID: 9672070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study.
    Wu TT; Zheng YY; Yang YN; Li XM; Ma YT; Xie X
    Metab Syndr Relat Disord; 2019 May; 17(4):223-231. PubMed ID: 30720383
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
    Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
    Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
    Holme I; Strandberg TE; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Larsen ML; Lindahl C; Pedersen TR;
    Atherosclerosis; 2009 Aug; 205(2):522-7. PubMed ID: 19327776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease.
    Göçmen AY; Gümüşlü S; Semiz E
    Clin Cardiol; 2004 Jul; 27(7):426-30. PubMed ID: 15298047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
    Cubrilo-Turek M; Sertić J; Duraković Z
    Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.
    Hasler-Rapacz J; Kempen HJ; Princen HM; Kudchodkar BJ; Lacko A; Rapacz J
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):137-43. PubMed ID: 8548414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol.
    Miller M; Seidler A; Kwiterovich PO; Pearson TA
    Circulation; 1992 Oct; 86(4):1165-70. PubMed ID: 1394924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
    Kastelein JJ; van der Steeg WA; Holme I; Gaffney M; Cater NB; Barter P; Deedwania P; Olsson AG; Boekholdt SM; Demicco DA; Szarek M; LaRosa JC; Pedersen TR; Grundy SM; ;
    Circulation; 2008 Jun; 117(23):3002-9. PubMed ID: 18519851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.
    Liem AH; van de Woestijne AP; Roeters van Lennep HW; Zwinderman AH; van der Steeg WA; Jukema JW
    Curr Med Res Opin; 2008 Feb; 24(2):359-64. PubMed ID: 18081989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum high-density lipoprotein-cholesterol levels modify the association between plasma levels of oxidatively modified low-density lipoprotein and coronary artery disease in men.
    Zhang B; Bai H; Liu R; Kumagai K; Itabe H; Takano T; Saku K
    Metabolism; 2004 Apr; 53(4):423-9. PubMed ID: 15045686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
    Walldius G; Jungner I; Holme I; Aastveit AH; Kolar W; Steiner E
    Lancet; 2001 Dec; 358(9298):2026-33. PubMed ID: 11755609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
    Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
    Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
    Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJ; Bittner V; Fruchart JC;
    N Engl J Med; 2007 Sep; 357(13):1301-10. PubMed ID: 17898099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.